Plant-based oral vaccines: results of human trials.
Vaccines consisting of transgenic plant-derived antigens offer a new strategy for development of safe, inexpensive vaccines. The vaccine antigens can be eaten with the edible part of the plant or purified from plant material. In phase 1 clinical studies of prototype potato- and corn-based vaccines, these vaccines have been safe and immunogenic without the need for a buffer or vehicle other than the plant cell. Transgenic plant technology is attractive for vaccine development because these vaccines are needle-less, stable, and easy to administer. This chapter examines some early human studies of oral transgenic plant-derived vaccines against enterotoxigenic Escherichia coli infection, norovirus, and hepatitis B.
Tacket
C O
CO
Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore St., Baltimore, MD 21201, USA. ctacket@medicine.umaryland.edu
D000284:Administration, Oral; D002986:Clinical Trials as Topic; D022361:Escherichia coli Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000096:biosynthesis / Q000276:immunology; D006801:Humans; D030821:Plants, Genetically Modified / Q000235:genetics* / Q000378:metabolism*; D011198:Solanum tuberosum / Q000235:genetics / Q000378:metabolism; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000009:adverse effects / Q000096:biosynthesis* / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000096:biosynthesis / Q000276:immunology; D003313:Zea mays / Q000235:genetics / Q000378:metabolism
D022361:Escherichia coli Vaccines; D022223:Vaccines, Subunit; D014765:Viral Vaccines